一品红：全资子公司创新药APH03621片获得临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for its innovative drug APH03621, which is set to enter clinical trials soon, marking a significant advancement in the treatment of endometriosis with no existing oral GnRH antagonists approved in the domestic market [1] Company Summary - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., is responsible for the development of APH03621 [1] - APH03621 is a novel oral, non-peptide small molecule GnRH receptor antagonist [1] Industry Summary - The drug is intended for the treatment of endometriosis, a condition that currently lacks approved oral GnRH antagonists in the domestic market [1]